See related research by Brkic et al., http://arthritis-research.com/content/16/2/R62 and related letter by Brkic et al.,
We read with great interest the article by Brkic and colleagues in a recent issue of Arthritis Research & Therapy [1] . In that study, the authors investigated the distribution of T helper (Th) subsets which produce IL-17A, IL-17 F, IL-21, and IL-22 in patients with systemic lupus erythematosus (SLE) in relation to their genetic IFN type I signature. Patients with an IFN type I-positive signature showed increased percentages of IL-17A-and IL-21-producing CCR6 + T cells. From these results, the authors conclude that IFN type I cells co-act with Th17 cytokines in the pathogenesis of SLE. Surprisingly, they excluded CD25 + T cells from their analysis. In a previous study, we showed that Th cells from SLE patients expressing CD25 med and CD25 high are also able to produce IFN-γ and IL-17A [2] . Therefore, it would be relevant to assess cytokine expression in CD4 + CD25 + T cells from IFN type I-positive and IFN type I-negative SLE patients. Furthermore, it should be proven that the genetic signature is solely responsible for the increased IFN production by Th cells. In addition, their finding that CCR6 + T cells are capable of producing IL-21 indirectly confirms our previous observation that IL-17 + T cells are a main source of IL-21 in patients with SLE [3] . Possibly, IL-21 is orchestrating the Th1/Th17 axis.
Finally, we agree that there might be a co-activity between IFN-I-and IL-17-producing cells as described by Brkic and colleagues. However, considering our findings that T cells with a regulatory phenotype are able to produce IFN-γ and IL-17A in patients with SLE, we suggest that primarily the plasticity of T cells is altered in patients with SLE [4] . 
